The CEO Roundtable on Cancer elected Robert Bradway as its chairman at its recent annual meeting, CEO Roundtable-XIV. Bradway, chairman and chief executive officer of Amgen, will serve a three-year term.

The CEO Roundtable on Cancer, a nonprofit organization of executives, was founded by former President George H.W. Bush in 2001 with a mandate to bring bold and imaginative solutions to cancer treatment and prevention. The CEO-led effort has benefitted from a 14-year legacy of strong leadership, beginning with Bush’s appointments of former Chairs Robert Ingram, William Weldon and Christopher Viehbacher.

“The CEO Roundtable on Cancer is committed to the elimination of cancer as a public health issue,” said Bradway. “Our hope is that through powerful initiatives like the CEO Cancer Gold Standard accreditation and Project Data Sphere, we can facilitate better access to the best-available treatments, advance research and enhance prevention efforts.”

The CEO Roundtable on Cancer has led efforts in both global health and research innovation, as well as its deep commitment to employee wellness through its CEO Cancer Gold Standard workplace accreditation program. The Gold Standard recognizes employers’ efforts to build a culture of wellness by promoting healthy lifestyle choices, encouraging cancer screening and promoting access to quality cancer treatment.

Globally, CEOs from many industries are keenly aware of the life-improving impact they can have on both health and controlling healthcare costs when they address cancer and other chronic diseases. In 2012, under the chairmanship of Viehbacher, the CEO Roundtable on Cancer began working in China with government, industry and international cancer experts to bring the benefits of the Gold Standard to the world’s most populated country.

Organizations that have provided clinical trial data to the digital library-laboratory include Amgen, AstraZeneca, Bayer, Celgene, EMD Serono, Johnson & Johnson, Eli Lilly, Memorial Sloan-Kettering Cancer Center, Pfizer, Synta, Sanofi and The Alliance for Clinical Trials in Oncology, one of the five U.S. network groups of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN).